Merck Earnings Preview: Not Much To Fear, Plenty To Look Forward To [Seeking Alpha]
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: Seeking Alpha
Some companies within the big pharma sector have underperformed due to government pressure on drug pricing and patent expirations. Merck's future looks promising, however, despite its looming Keytruda patent expiry, with a strong pipeline of drugs and potential for extended patent protection for its top-selling drug. There ought to plenty of positives around next weeks earnings - the company's M&A and R&D spending has brought several new drugs to the brink of approval. The dividend yields ~2.5% at a time of writing. And after earnings dropped substantially in 2023, a return to strong profitability - unless further M&A activity happens - will keep the share price buoyant. Investment Overview Merck & Co., Inc. ( NYSE: MRK ) will announce its Q1 2024 earnings next Thursday, April 25. Analysts' consensus opinion is that earnings per share will be in the region of $1.99 on a normalized basis, or $1.87 on a GAAP basis, on revenues of ~$15.2bn. Big pharma is generally regarded a
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- Polylysine Sales to Rise at 10.1% CAGR through 2034 Amid Escalating Demand for Natural Preservatives [Yahoo! Finance]Yahoo! Finance
- Global Active Pharmaceutical Ingredients Market Analysis Report 2024-2030: Synthetic API Segment Dominated the Market with the Largest Revenue Share of 70.6% in 2023 [Yahoo! Finance]Yahoo! Finance
- Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults [Yahoo! Finance]Yahoo! Finance
- Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for AdultsBusiness Wire
- Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Global Clinical Trials Review 2024: G7 & E7 Regional Insights, Phase, Trial Status, End-points Status and Sponsor Type [Yahoo! Finance]Yahoo! Finance
MRK
Earnings
- 4/25/24 - Beat
MRK
Sec Filings
- 4/25/24 - Form 8-K
- 4/11/24 - Form ARS
- 4/11/24 - Form DEFA14A
- MRK's page on the SEC website